The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma

Cancer

Volumn 121, Issue 24, 2015, Pages 4333-4340

  Wong, Stephanie M ^a,b   Freedman, Rachel A ^c   Sagara, Yasuaki ^d   Stamell, Emily F ^a,c   Desantis, Stephen D ^c,d   Barry, William T ^c   Golshan, Mehra ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

and End Results; breast neoplasms; cancer outcomes; Epidemiology; Paget disease of the breast; prognosis; Surveillance; survival

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; AXILLARY LYMPH NODE METASTASIS; BREAST CARCINOMA; CANCER MORTALITY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; AXILLA; BREAST NEOPLASMS; CANCER REGISTRY; CARCINOMA, DUCTAL, BREAST; COMPLICATION; FACTUAL DATABASE; KAPLAN MEIER METHOD; LYMPH NODE; METABOLISM; MIDDLE AGED; PAGET'S DISEASE, MAMMARY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEGMENTAL MASTECTOMY; TUMOR VOLUME;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DATABASES, FACTUAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; PAGET'S DISEASE, MAMMARY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SEER PROGRAM; TUMOR BURDEN;

EID: 84949316017     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29687     Document Type: Article

References (29)

1. Ashikari R, Park K, Huvos AG, Urban JA., Paget's disease of the breast. Cancer. 1970; 26: 680-685.
2. Dalberg K, Hellborg H, Warnberg F., Paget's disease of the nipple in a population based cohort. Breast Cancer Res Treat. 2008; 111: 313-319.
3. Sandoval-Leon AC, Drews-Elger K, Gomez-Fernandez CR, et al., Paget's disease of the nipple. Breast Cancer Res Treat. 2013; 141: 1-12.
4. Paone JF, Baker RR., Pathogenesis and treatment of Paget's disease of the breast. Cancer. 1981; 48: 825-829.
5. Yim JH, Wick MR, Philpott GW, et al., Underlying pathology in mammary Paget's disease. Ann Surg Oncol. 1997; 4: 287-292.
6. Lagios MD, Westdahl PR, Rose MR, Concannon S., Paget's disease of the nipple. Alternative management in cases without or with minimal extent of underlying breast carcinoma. Cancer. 1984; 54: 545-551.
7. Chen CY, Sun LM, Anderson BO., Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the United States. Cancer. 2006; 107: 1448-1458.
8. Fu W, Mittel VK, Young SC., Paget disease of the breast: analysis of 41 patients. Am J Clin Oncol. 2001; 24: 397-400.
9. Sakorafas GH, Blanchard K, Sarr MG, Farley DR., Paget's disease of the breast. Cancer Treat Rev. 2001; 27: 9-18.
10. Sek P, Zawrocki A, Biernat W, Piekarski JH., HER2 molecular subtype is a dominant subtype of mammary Paget's cells. An immunohistochemical study. Histopathology. 2010; 57: 564-571.
11. Durkan B, Bresee C, Bose S, et al., Paget's disease of the nipple with parenchymal ductal carcinoma in situ is associated with worse prognosis than Paget's disease alone. Am Surg. 2013; 79: 1009-1012.
12. Ling H, Hu X, Xu XL, et al., Patients with nipple-areola Paget's disease and underlying invasive breast carcinoma have very poor survival: a matched cohort study [serial online]. PLoS One. 2013; 8: e61455.
13. Ortiz-Pagan S, Cunto-Amesty G, Narayan S, et al., Effect of Paget's disease on survival in breast cancer: an exploratory study. Arch Surg. 2011; 146: 1267-1270.
14. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
15. Wang J, Mittendorf EA, Sahin AA, et al., Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the Surveillance, Epidemiology, and End Results (SEER) database [serial online]. PLoS One. 2014; 9: e89778.
16. Caliskan M, Gatti G, Sosnovskikh I, et al., Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2008; 112: 513-521.
17. Chaudary MA, Millis RR, Lane EB, Miller NA., Paget's disease of the nipple: a 10-year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat. 1986; 8: 139-146.
18. Nance FC, DeLoach DH, Welsh RA, Becker WF., Paget's disease of the breast. Ann Surg. 1970; 171: 864-874.
19. Siponen E, Hukkinen K, Heikkila P, et al., Surgical treatment in Paget's disease of the breast. Am J Surg. 2010; 200: 241-246.
20. Kollmorgen DR, Varanasi JS, Edge SB, Carson WE 3rd,. Paget's disease of the breast: a 33-year experience. J Am Coll Surg. 1998; 187: 171-177.
21. Kothari AS, Beechey-Newman N, Hamed H, et al., Paget disease of the nipple: a multifocal manifestation of higher-risk disease. Cancer. 2002; 95: 1-7.
22. Bevilacqua J, Cody H 3rd, MacDonald KA, et al., A prospective validated model for predicting axillary node metastases based on 2,000 sentinel node procedures: the role of tumour location [corrected]. Eur J Surg Oncol. 2002; 28: 490-500.
23. Yoshihara E, Smeets A, Laenen A, et al., Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. Breast. 2013; 22: 357-361.
24. Wolber RA, Dupuis BA, Wick MR., Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol. 1991; 96: 243-247.
25. Wolf-Yadlin A, Kumar N, Zhang Y, et al., Effects of HER2 overexpression on cell signaling networks governing proliferation and migration [serial online]. Mol Syst Biol. 2006; 2: 54.
26. Reese DM, Slamon DJ., HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 1997; 15: 1-8.
27. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al., Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809-820.
28. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
29. Romond EH, Perez EA, Bryant J, et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.